A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator Publication A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator This collaborative effort by Certara and the Centre for Applied Pharmacokinetic Research (CAPKR) at The…CertaraJuly 24, 2024
A literature review of drug transport mechanisms during lactation Publication A literature review of drug transport mechanisms during lactation The literature review titled "A literature review of drug transport mechanisms during lactation," authored by…CertaraJuly 7, 2024
Reflections on the new FDA clinical pharmacology guidance for antibody-drug conjugates Blog Reflections on the new FDA clinical pharmacology guidance for antibody-drug conjugates In recent years, oncology drug developers have invested in antibody-drug conjugates (ADCs). These targeted therapies…CertaraMay 10, 2024
Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator Publication Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator The Simcyp Simulator is a software platform for population physiologically-based pharmacokinetic (PBPK) modeling and simulation.…CertaraFebruary 23, 2024
What is kanban and how does it optimize early drug discovery projects? Blog What is kanban and how does it optimize early drug discovery projects? Discover how Kanban optimizes early drug discovery projects. Visualize workflow, improve collaboration, and increase productivity…CertaraSeptember 27, 2023
Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome Publication Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome Madin–Darby canine kidney (MDCK) cells are widely used to study epithelial cell functionality. Their low…CertaraJune 28, 2023
American College of Toxicology 2026 Annual Meeting Conference American College of Toxicology 2026 Annual Meeting – – BoothKevin Snyder, PhDMay 24, 2023
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150 Publication Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150 Explore how tumor growth inhibition modeling can support go/no-go decisions in early Phase Ib/II oncology…CertaraMarch 24, 2023